DBV Technologies S.A. (EPA: DBV)
France
· Delayed Price · Currency is EUR
0.525
-0.015 (-2.78%)
Nov 20, 2024, 5:35 PM CET
DBV Technologies Revenue
DBV Technologies had revenue of $1.07M USD in the quarter ending September 30, 2024, a decrease of -54.81%. This brings the company's revenue in the last twelve months to $12.52M, up 125.54% year-over-year. In the year 2023, DBV Technologies had annual revenue of $15.73M with 224.69% growth.
Revenue (ttm)
$12.52M
Revenue Growth
+125.54%
P/S Ratio
4.50
Revenue / Employee
$119.19K
Employees
105
Market Cap
50.66M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | 14.71M | 3.52M | 31.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech S.A. | 2.74B |
bioMérieux S.A. | 3.81B |
Ipsen S.A. | 3.44B |
Eurofins Scientific SE | 6.72B |
Virbac SA | 1.34B |
Ramsay Générale de Santé SA | 5.01B |
DBV Technologies News
- 6 days ago - BRAIDWELL LP's Strategic Acquisition in DBV Technologies SA - GuruFocus
- 9 days ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire
- 14 days ago - DBV Technologies GAAP EPS of -$0.32 beats by $0.03 - Seeking Alpha
- 14 days ago - DBV Technologies Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway - Benzinga
- 4 weeks ago - DBV Tech spikes after regulatory update on lead asset - Seeking Alpha
- 4 weeks ago - Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Benzinga
- 4 weeks ago - DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewsWire